SPINK1 protein expression and prostate cancer progression

Area of Science:

• Oncology
• Urology
• Cancer Biomarkers

Background:

• Serrate protease inhibitor Kazal type 1 (SPINK1) is overexpressed in prostate cancer.
• SPINK1 overexpression is associated with poor prognosis in various cancers.
• The prognostic significance of SPINK1 in prostate cancer requires further elucidation.

Purpose of the Study:

• To investigate the association between SPINK1 overexpression and prostate cancer-specific survival.
• To determine if SPINK1 expression predicts recurrence or mortality after radical prostatectomy.

Main Methods:

• Analysis of 879 prostate cancer patients from the U.S. Physicians' Health Study and Health Professionals Follow-Up Study.
• Immunohistochemistry used to assess SPINK1 protein expression in tumor tissues.
• Evaluation of associations between SPINK1 status and clinical outcomes, including recurrence and mortality.

Main Results:

• SPINK1 protein was overexpressed in 8% of prostate tumors.
• SPINK1-positive tumors exhibited higher PTEN and stathmin expression, and lower androgen receptor (AR) expression.
• No significant association was found between SPINK1 expression and Gleason grade, tumor stage, biochemical recurrence, or prostate cancer mortality.

Conclusions:

• SPINK1 protein expression is not a significant predictor of recurrence or lethal prostate cancer in men treated with radical prostatectomy.
• SPINK1 and ERG protein expression can co-exist in prostate tumors, challenging previous assumptions of mutual exclusivity.